Biohaven Ev To Free Cash Flow vs Cash Ratio Analysis

BHVN Stock

USD 42.81 0.22 0.52%

Biohaven Pharmaceutical financial indicator trend analysis is way more than just evaluating Biohaven Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biohaven Pharmaceutical is a good investment. Please check the relationship between Biohaven Pharmaceutical Ev To Free Cash Flow and its Cash Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Ev To Free Cash Flow vs Cash Ratio

Ev To Free Cash Flow vs Cash Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biohaven Pharmaceutical Ev To Free Cash Flow account and Cash Ratio. At this time, the significance of the direction appears to have strong relationship.

The correlation between Biohaven Pharmaceutical's Ev To Free Cash Flow and Cash Ratio is 0.78. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Cash Ratio in the same time period over historical financial statements of Biohaven Pharmaceutical Holding, assuming nothing else is changed. The correlation between historical values of Biohaven Pharmaceutical's Ev To Free Cash Flow and Cash Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of Biohaven Pharmaceutical Holding are associated (or correlated) with its Cash Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Ratio has no effect on the direction of Ev To Free Cash Flow i.e., Biohaven Pharmaceutical's Ev To Free Cash Flow and Cash Ratio go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Cash Ratio

Most indicators from Biohaven Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biohaven Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

At this time, Biohaven Pharmaceutical's Selling General Administrative is very stable compared to the past year. As of the 11th of December 2024, Enterprise Value is likely to grow to about 3 B, though Tax Provision is likely to grow to (1.3 M).

	2022	2023	2024 (projected)
Interest Expense	1.4M	1.2M	1.2M
Depreciation And Amortization	1.4M	6.9M	7.3M

Interest Expense Depreciation And Amortization

Biohaven Pharmaceutical fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Other Liab	Net Tangible Assets	Current Deferred Revenue	Other Assets	Net Receivables	Short Term Investments
Total Assets		0.64	0.87	0.81	0.84	-0.38	0.16	0.83	0.66	0.83	-0.4	0.98	0.44	0.34	0.93	-0.11	0.53	1.0	0.18	-0.36	0.61	0.69	-0.88	0.04	-0.58	-0.18
Other Current Liab	0.64		0.92	0.27	0.68	0.13	-0.55	0.67	0.46	0.7	-0.64	0.61	0.09	0.57	0.54	0.61	0.73	0.61	0.77	0.33	0.64	0.2	-0.54	0.21	-0.64	-0.33
Total Current Liabilities	0.87	0.92		0.55	0.81	-0.05	-0.27	0.73	0.52	0.83	-0.61	0.82	0.13	0.47	0.79	0.32	0.67	0.85	0.56	0.06	0.66	0.41	-0.74	0.27	-0.66	-0.16
Total Stockholder Equity	0.81	0.27	0.55		0.86	-0.37	0.39	0.52	0.25	0.75	-0.39	0.75	0.52	-0.15	0.94	-0.32	0.02	0.79	-0.03	-0.6	0.64	0.82	-0.95	-0.15	-0.64	-0.31
Property Plant And Equipment Net	0.84	0.68	0.81	0.86		-0.07	-0.1	0.63	0.28	0.92	-0.71	0.75	0.41	0.05	0.93	0.17	0.26	0.8	0.47	-0.22	0.86	0.66	-0.97	-0.01	-0.86	-0.49
Net Debt	-0.38	0.13	-0.05	-0.37	-0.07		-0.84	-0.47	-0.62	0.14	-0.42	-0.51	-0.56	-0.37	-0.33	0.76	-0.32	-0.44	0.67	0.85	0.27	-0.72	0.27	0.66	-0.29	-0.05
Retained Earnings	0.16	-0.55	-0.27	0.39	-0.1	-0.84		0.07	0.23	-0.24	0.52	0.25	0.41	-0.11	0.22	-0.97	-0.17	0.22	-0.92	-0.9	-0.37	0.57	-0.15	-0.48	0.39	0.24
Accounts Payable	0.83	0.67	0.73	0.52	0.63	-0.47	0.07		0.9	0.6	-0.14	0.89	0.63	0.67	0.65	0.03	0.76	0.84	0.23	-0.25	0.52	0.56	-0.64	-0.24	-0.47	-0.43
Cash	0.66	0.46	0.52	0.25	0.28	-0.62	0.23	0.9		0.26	0.21	0.78	0.48	0.82	0.4	-0.16	0.84	0.71	-0.03	-0.29	0.11	0.43	-0.33	-0.25	-0.06	-0.11
Non Current Assets Total	0.83	0.7	0.83	0.75	0.92	0.14	-0.24	0.6	0.26		-0.74	0.72	0.33	0.0	0.84	0.26	0.24	0.78	0.54	0.0	0.9	0.43	-0.87	0.26	-0.87	-0.41
Non Currrent Assets Other	-0.4	-0.64	-0.61	-0.39	-0.71	-0.42	0.52	-0.14	0.21	-0.74		-0.25	-0.03	0.22	-0.51	-0.48	0.01	-0.33	-0.7	-0.22	-0.69	-0.24	0.59	-0.2	0.68	0.36
Cash And Short Term Investments	0.98	0.61	0.82	0.75	0.75	-0.51	0.25	0.89	0.78	0.72	-0.25		0.49	0.47	0.87	-0.18	0.63	0.99	0.09	-0.43	0.5	0.72	-0.81	-0.07	-0.47	-0.16
Common Stock Shares Outstanding	0.44	0.09	0.13	0.52	0.41	-0.56	0.41	0.63	0.48	0.33	-0.03	0.49		0.07	0.41	-0.35	0.09	0.45	-0.18	-0.56	0.41	0.64	-0.52	-0.67	-0.33	-0.71
Non Current Liabilities Total	0.34	0.57	0.47	-0.15	0.05	-0.37	-0.11	0.67	0.82	0.0	0.22	0.47	0.07		0.09	0.21	0.97	0.39	0.2	0.1	-0.07	0.08	0.0	-0.11	0.07	0.02
Other Current Assets	0.93	0.54	0.79	0.94	0.93	-0.33	0.22	0.65	0.4	0.84	-0.51	0.87	0.41	0.09		-0.14	0.29	0.91	0.16	-0.45	0.68	0.78	-0.97	-0.01	-0.68	-0.24
Other Stockholder Equity	-0.11	0.61	0.32	-0.32	0.17	0.76	-0.97	0.03	-0.16	0.26	-0.48	-0.18	-0.35	0.21	-0.14		0.27	-0.17	0.94	0.87	0.44	-0.5	0.08	0.41	-0.48	-0.33
Total Liab	0.53	0.73	0.67	0.02	0.26	-0.32	-0.17	0.76	0.84	0.24	0.01	0.63	0.09	0.97	0.29	0.27		0.56	0.32	0.11	0.12	0.17	-0.2	0.0	-0.12	-0.01
Total Current Assets	1.0	0.61	0.85	0.79	0.8	-0.44	0.22	0.84	0.71	0.78	-0.33	0.99	0.45	0.39	0.91	-0.17	0.56		0.12	-0.41	0.55	0.71	-0.85	0.0	-0.52	-0.14
Common Stock	0.18	0.77	0.56	-0.03	0.47	0.67	-0.92	0.23	-0.03	0.54	-0.7	0.09	-0.18	0.2	0.16	0.94	0.32	0.12		0.7	0.64	-0.22	-0.23	0.35	-0.66	-0.43
Short Long Term Debt Total	-0.36	0.33	0.06	-0.6	-0.22	0.85	-0.9	-0.25	-0.29	0.0	-0.22	-0.43	-0.56	0.1	-0.45	0.87	0.11	-0.41	0.7		0.15	-0.84	0.43	0.65	-0.17	-0.01
Other Liab	0.61	0.64	0.66	0.64	0.86	0.27	-0.37	0.52	0.11	0.9	-0.69	0.5	0.41	-0.07	0.68	0.44	0.12	0.55	0.64	0.15		0.29	-0.77	0.15	-0.99	-0.69
Net Tangible Assets	0.69	0.2	0.41	0.82	0.66	-0.72	0.57	0.56	0.43	0.43	-0.24	0.72	0.64	0.08	0.78	-0.5	0.17	0.71	-0.22	-0.84	0.29		-0.8	-0.59	-0.27	-0.28
Current Deferred Revenue	-0.88	-0.54	-0.74	-0.95	-0.97	0.27	-0.15	-0.64	-0.33	-0.87	0.59	-0.81	-0.52	0.0	-0.97	0.08	-0.2	-0.85	-0.23	0.43	-0.77	-0.8		0.12	0.76	0.43
Other Assets	0.04	0.21	0.27	-0.15	-0.01	0.66	-0.48	-0.24	-0.25	0.26	-0.2	-0.07	-0.67	-0.11	-0.01	0.41	0.0	0.0	0.35	0.65	0.15	-0.59	0.12		-0.19	0.47
Net Receivables	-0.58	-0.64	-0.66	-0.64	-0.86	-0.29	0.39	-0.47	-0.06	-0.87	0.68	-0.47	-0.33	0.07	-0.68	-0.48	-0.12	-0.52	-0.66	-0.17	-0.99	-0.27	0.76	-0.19		0.66
Short Term Investments	-0.18	-0.33	-0.16	-0.31	-0.49	-0.05	0.24	-0.43	-0.11	-0.41	0.36	-0.16	-0.71	0.02	-0.24	-0.33	-0.01	-0.14	-0.43	-0.01	-0.69	-0.28	0.43	0.47	0.66

Click cells to compare fundamentals

Biohaven Pharmaceutical Account Relationship Matchups

Biohaven Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	344.3M	111.5M	142.1M	661.8M	513.2M	347.2M
Other Current Liab	52.1M	27.1M	37.2M	38.1M	36.5M	32.1M
Total Current Liabilities	66.2M	29.9M	41.9M	90.0M	55.4M	49.1M
Total Stockholder Equity	(7.4M)	16.8M	34.7M	538.8M	428.0M	449.4M
Property Plant And Equipment Net	8.2M	13.6M	18.2M	52.4M	48.6M	51.0M
Net Debt	(316.7M)	185.0M	550.7M	(174.3M)	(217.5M)	(206.6M)
Retained Earnings	(972.4M)	(1.7B)	(2.6B)	(91.1M)	(499.3M)	(524.3M)
Accounts Payable	14.1M	2.8M	4.8M	10.7M	15.6M	10.0M
Cash	316.7M	82.5M	76.1M	204.9M	248.4M	151.3M
Non Current Assets Total	16.0M	21.7M	47.2M	74.8M	70.8M	40.6M
Non Currrent Assets Other	7.8M	1.0M	3.2M	2.6M	2.4M	4.2M
Cash And Short Term Investments	316.7M	82.5M	76.1M	465.3M	381.8M	270.0M
Liabilities And Stockholders Equity	344.3M	111.5M	142.1M	661.8M	513.2M	347.2M
Non Current Liabilities Total	285.5M	4.8M	5.4M	33.0M	29.8M	55.3M
Other Current Assets	11.6M	10K	2.1M	75.5M	47.4M	49.7M
Other Stockholder Equity	83.5M	98.9M	169.7M	13.9M	39.8M	73.8M
Total Liab	351.7M	34.7M	47.4M	123.0M	85.2M	91.0M
Total Current Assets	328.3M	89.8M	94.8M	587.0M	442.4M	306.6M
Common Stock	881.4M	1.2B	1.7B	615.7M	887.5M	970.6M

Pair Trading with Biohaven Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving against Biohaven Stock

0.54	PTN	Palatin Technologies	Pair Corr
0.39	DYAI	Dyadic International	Pair Corr
0.34	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.

The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Biohaven Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biohaven Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biohaven Pharmaceutical Holding Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biohaven Pharmaceutical Holding Stock:

How To Invest In Biohaven

Details

Is Biohaven Stock a good investment?

Details

What is Biohaven Pharmaceutical's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(9.37)

Return On Assets

(1.19)

Return On Equity

(2.65)

The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biohaven Ev To Free Cash Flow vs Cash Ratio Analysis

Ev To Free Cash Flow vs Cash Ratio

Ev To Free Cash Flow vs Cash Ratio Correlation Analysis

Correlation Coefficient

Ev To Free Cash Flow

Cash Ratio

Biohaven Pharmaceutical fundamental ratios Correlations

Biohaven Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biohaven Pharmaceutical fundamental ratios Accounts

Pair Trading with Biohaven Pharmaceutical

Moving against Biohaven Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.98	Total Assets
Total Liab	+ 0.97	Non Current Liabilities Total
Other Current Assets	+ 0.94	Total Stockholder Equity
Common Stock	+ 0.94	Other Stockholder Equity

Net Receivables	- 0.99	Other Liab
Current Deferred Revenue	- 0.97	Other Current Assets
Other Stockholder Equity	- 0.97	Retained Earnings
Current Deferred Revenue	- 0.97	Property Plant And Equipment Net
Current Deferred Revenue	- 0.95	Total Stockholder Equity
Common Stock	- 0.92	Retained Earnings